News

The House Energy and Commerce and House Ways and Means Committees recently held hearings on the rising cost of healthcare, shining a spotlight on how PBMs and insurers are driving out-of-pocket costs for prescriptions and why reform is urgently needed.   Members from both parties agree that PBMs and other insurance middlemen are limiting access and raising costs. As Chairman Morgan Griffith (R-VA) emphasized in his opening remarks the lack of transparency and complexity of t

The U.S. House of Representatives today advanced the bipartisan spending bill with several PBM reforms. Mark Blum, managing director of the PBM Accountability Project, issued the following statement: “Today’s House vote advances long-overdue PBM reforms that rein in abusive corporate middlemen practices, marking a critical step toward making healthcare more affordable for Americans. The Senate must now act without delay to put patients over profiteers and send this package t

The House Judiciary Committee today released an interim staff report " When CVS Writes the Rules: How CVS Protects Itself From Innovation and Competition ," unveiling how CVS Health leveraged its PBM and adjusted its business practices to eliminate independent pharmacy competition. As the Committee's press release points out, "CVS Health's own CEO characterized his company's actions best by writing: 'another example of a large PBM not allowing the small guys to compete.'" To

Congressional leaders released a bipartisan spending bill with several key provisions to lower out-of-pocket costs for prescriptions, increase transparency, and support patients and independent pharmacies that pharmacy benefit managers (PBMs) have long taken advantage of. Mark Blum, managing director of the PBM Accountability Project, issued the following statement:   “We are pleased to see Congress put forward a spending package that finally begins to take on the most power

President Trump recently called upon Congress to enact “The Great Healthcare Plan ,” legislation aimed at reducing healthcare costs for Americans, in part, by targeting the practices of big health insurance companies and their affiliated pharmacy benefit managers (PBMs). PBM Accountability Project Managing Director Mark Blum issued the following statement:    “We commend the Trump Administration for insisting that Congress make healthcare affordability a priority in 2026. We

The PBM Accountability Project members and partners are highlighting a shared concern: PBMs and vertically integrated insurers are creating real barriers to patient affordability and access.  Watch new video testimonials underscor ing the urgent need for meaningful PBM reform: Emma Freer, Senior Health Policy Analyst, American Economic Liberties Project   How has vertical integration in the health insurance industry affected patient choice, medication access and drug pricing

A new investigation by Hunterbrook takes a closer look at little-known subsidiaries, known as group purchasing organizations (GPOs), in the U.S. prescription drug market.   As the PBM Accountability Project has previously called out since the first GPO was established in 2020, these shell companies were created by major health insurers and affiliated PBMs, allowing these conglomerates to quietly keep billions meant to lower employers’ and patients’ drug costs, even while p

(OptumRx, owned by UnitedHealth Group)   It’s been well reported that the top three PBMs control nearly 80% of all U.S. prescription drug claims . They were originally established to negotiate prescription drug savings for patients, employers and taxpayers – and yet, Americans continue to face higher out-of-pocket costs for the medicines they need.    So, who are these PBMs and how can we separate fact from fiction?    Let’s take a closer look at the Big Three corporate middl

(CVS Caremark, owned by CVS Health)   It’s been well reported that the top three PBMs control nearly 80% of all U.S. prescription drug claims . They were originally established to negotiate prescription drug savings for patients, employers and taxpayers – and yet, Americans continue to face higher out-of-pocket costs for the medicines they need.   So, who are these PBMs and how can we separate fact from fiction?   Let’s take a closer look at the Big Three corporate middlemen

(Express Scripts, owned by Cigna) It’s been well reported that the top three PBMs control nearly 80% of all U.S. prescription drug claims . They were originally established to negotiate prescription drug savings for patients, employers and taxpayers – and yet, Americans continue to face higher out-of-pocket costs for the medicines they need.   So, who are these PBMs and how can we separate fact from fiction?   Let’s take a closer look at the Big Three corporate middlemen in t

As 2025 comes to a close, President Trump announced his Administration’s plans to convene health insurance CEOs in an effort to address their role in driving up healthcare costs for the American people. PBM Accountability Project Managing Director Mark Blum issued the following statement:   “We are pleased to see President Trump and his Administration’s attention on the corporate insurers and PBMs that currently dominate the healthcare system and play a significant role in dr

As 2025 comes to a close, one thing is clear: momentum for PBM reform is stronger than ever. Over the past year, patients, pharmacists, employers and policymakers have increasingly recognized what the PBM Accountability Project (PBMA) has long worked to expose. The current PBM middleman system drives up costs, limits patient choice and operates with far too little transparency. The growing recognition for PBM accountability translated into meaningful action at both the state